MedTrace Logo

Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia

NCT03378414 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-04-23

No results posted yet for this study

Summary

The purpose of this study is verify the safety and efficacy of Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC) therapy for patients with Spinocerebellar Ataxia, and in addition, explore the possible mechanisms of UC-MSC therapy in Spinocerebellar Ataxia.

Conditions

  • Spinocerebellar Ataxia Type 1
  • Spinocerebellar Ataxia Type 2
  • Spinocerebellar Ataxia Type 3
  • Spinocerebellar Ataxia Type 6

Interventions

PROCEDURE

Intravenous infusion

Intravenous infusion of mesenchymal stem cells: 2 \* 10\^7 cells (30ml)

PROCEDURE

Intrathecal injection

Intrathecal injection of mesenchymal stem cells: 2 \* 10\^7 cells (1ml)

BIOLOGICAL

umbilical cord mesenchymal stem cell

Treat patients with umbilical cord mesenchymal stem cell (SCLnow 19#), the dosage based on different procedure

Sponsors & Collaborators

  • Sclnow Biotechnology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Hong Jiang · Xiangya Hospital of Central South University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-12-31
Primary Completion
2027-06-30
Completion
2027-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03378414 on ClinicalTrials.gov